alpha-MSH analog is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-04-24. Numbers and descriptions here follow the published literature rather than marketing material.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
=== March === March 30, 2011: Wales The global credit information group Experian highlighted in a report that the economic recovery for Wales is slower than the rest of the UK, stating a forecasted growth of 1.6% per year over the next decade as compared to 2.2% for the rest of the United Kingdom. Issues for Wales were attributed to low export rates, an unskilled workforce and low entrepreneurism, leading to less opportunities for growth.
=== Differential diagnosis === Several diseases present similarly to MS. Medical professionals use the specific presentation, history, and exam findings to make an individualized differential. Red flags are findings that suggest an alternate diagnosis, although they do not rule out MS. They include individuals being younger than 11 or older than 50, signs of nerve damage outside of the central nervous system, severe vision loss, a very rapid onset, or atypical lab and exam findings. A very rapid onset may indicate a stroke or seizure rather than MS. Intractable vomiting, severe optic neuritis, or bilateral optic neuritis raises suspicion for neuromyelitis optica spectrum disorder (NMOSD). Infectious diseases that may look similar to multiple sclerosis include HIV, Lyme disease, and syphilis. Autoimmune diseases include neurosarcoidosis, lupus, Guillain-Barré syndrome, acute disseminated encephalomyelitis, and Behçet's disease. Psychiatric conditions such as anxiety may also present in a similar way. Other rare diseases on the differential include CNS lymphoma, congenital leukodystrophies, and anti-MOG-associated myelitis.
Living organisms must obey the laws of thermodynamics, which describe the transfer of heat and work. The second law of thermodynamics states that in any isolated system, the amount of entropy (disorder) cannot decrease. Although living organisms' amazing complexity appears to contradict this law, life is possible as all organisms are open systems that exchange matter and energy with their surroundings. Living systems are not in equilibrium, but instead are dissipative systems that maintain their state of high complexity by causing a larger increase in the entropy of their environments. The metabolism of a cell achieves this by coupling the spontaneous processes of catabolism to the non-spontaneous processes of anabolism. In thermodynamic terms, metabolism maintains order by creating disorder.
Sources: en.wikipedia.org
Singapore is a major international transport hub in Asia, serving some of the busiest sea and air trade routes. Changi Airport is an aviation centre for Southeast Asia and a stopover on Qantas' Kangaroo Route between Sydney and London. There are two civilian airports in Singapore, Changi Airport and Seletar Airport. Changi Airport hosts a network of over 100 airlines connecting Singapore to some 300 cities in about 70 countries and territories worldwide. It has been rated one of the best international airports by international travel magazines, including being rated as the world's best airport for the first time in 2006 by Skytrax. It also had three of the ten busiest international air routes in the world in 2023: the busiest between Kuala Lumpur–Singapore, the seventh busiest between Jakarta–Singapore, and the ninth busiest between Bangkok–Singapore. Singapore Airlines, the flag carrier of Singapore, has been regarded as a 5-star airline by Skytrax and been in the world top 10 list of airlines for multiple consecutive years. It held the title of the World's Best Airline by Skytrax in 2023. It won this title 12 times. Its hub, Changi Airport had also been rated as the world's best airport from 2013 to 2020 before being superseded by Hamad International Airport in Doha. It reclaimed this title in 2023 before being superseded once more in 2024.
Lung disease: Lung cancer Interstitial lung disease most commonly idiopathic pulmonary fibrosis Complicated tuberculosis Suppurative lung disease: lung abscess, empyema, bronchiectasis, cystic fibrosis Mesothelioma of the pleura Sarcoidosis Heart disease: Any disease featuring chronic hypoxia Cyanotic heart defect (most common cardiac cause) Infective endocarditis Atrial myxoma (benign tumor) Arteriovenous fistula or malformation Gastrointestinal and hepatobiliary: Malabsorption Crohn's disease and ulcerative colitis Cirrhosis, especially in primary biliary cholangitis Hepatopulmonary syndrome, a complication of cirrhosis Others: Graves' disease (autoimmune hyperthyroidism) – in this case, it is known as thyroid acropachy Familial and hereditary clubbing and "pseudoclubbing" (people of African descent often have what appears to be clubbing) Vascular anomalies of the affected arm such as an axillary artery aneurysm (in unilateral clubbing) Primary hypertrophic osteoarthropathy Nail clubbing is not specific to chronic obstructive pulmonary disease (COPD). Therefore, in patients with COPD and significant degrees of clubbing, a search for signs of bronchogenic carcinoma (or other causes of clubbing) might still be indicated.
In vivo, phosphorolysis proceeds in the direction of glycogen breakdown because the ratio of phosphate and glucose-1-phosphate is usually greater than 100. Glucose-1-phosphate is then converted to glucose 6 phosphate (G6P) by phosphoglucomutase. A special debranching enzyme is needed to remove the α(1→6) branches in branched glycogen and reshape the chain into a linear polymer. The G6P monomers produced have three possible fates:
Sources: en.wikipedia.org
Baker has co-founded several biotechnology companies, including Prospect Genomics which was acquired by an Eli Lilly subsidiary in 2001, Icosavax which was acquired by AstraZeneca in 2023, Sana Biotechnology, Lyell Immunotherapeutics, Xaira Therapeutics and GenBio AI.
==== MeSH D12.776.860.300.250 – collagen ==== MeSH D12.776.860.300.250.300 – fibrillar collagens MeSH D12.776.860.300.250.300.100 – Type I collagen MeSH D12.776.860.300.250.300.200 – Type II collagen MeSH D12.776.860.300.250.300.300 – Type III collagen MeSH D12.776.860.300.250.300.400 – Type V collagen MeSH D12.776.860.300.250.300.500 – Type XI collagen MeSH D12.776.860.300.250.400 – non-fibrillar collagens MeSH D12.776.860.300.250.400.100 – Type IV collagen MeSH D12.776.860.300.250.400.200 – Type VI collagen MeSH D12.776.860.300.250.400.300 – Type VII collagen MeSH D12.776.860.300.250.400.400 – Type VIII collagen MeSH D12.776.860.300.250.400.500 – Type X collagen MeSH D12.776.860.300.250.400.525 – Type XIII collagen MeSH D12.776.860.300.250.400.537 – Type XVIII collagen MeSH D12.776.860.300.250.400.537.500 – endostatins MeSH D12.776.860.300.250.400.550 – fibril-associated collagens MeSH D12.776.860.300.250.400.550.200 – Type IX collagen MeSH D12.776.860.300.250.400.550.300 – Type XII collagen MeSH D12.776.860.300.250.600 – procollagen MeSH D12.776.860.300.250.700 – tropocollagen
== History == The oxymetazoline brand Afrin was first sold as a prescription medication in 1966. After finding substantial early success as a prescription medication, it became available as an over-the-counter drug in 1975. Schering-Plough did not engage in heavy advertising until 1986.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.